

Financial news for LGND dated on 2020-06-05: Stocks That Hit 52-Week Highs On Friday

Financial news for LGND dated on 2020-05-29: Ligand Pharma Reports Icagen To Expand Collaboration With Roche To Develop, Commercialize Therapies For Neurological Diseases, Co. Could Receive Up To \$274M In Milestone Payments

Financial news for LGND dated on 2020-05-28: Ligand Earns \$3M Milestone Payment From Palvella Therapeutics

Financial news for LGND dated on 2020-05-11: Biotech Stock Rally Is Crushing Short Sellers

Financial news for LGND dated on 2020-05-06: Ligand Pharmaceuticals shares are trading lower despite the company reporting better-than-expected Q1 EPS and sales results.

Financial news for LGND dated on 2020-05-06: Ligand Sees FY20 Sales Of \$140M And EPS \$3.65

Financial news for LGND dated on 2020-05-06: Ligand Pharmaceuticals Q1 EPS \$0.890 Beats \$0.660 Estimate, Sales \$33.200M Beat \$26.530M Estimate

Financial news for LGND dated on 2020-05-06: The Daily Biotech Pulse: FDA Nod For AstraZeneca, AbbVie-Allergan Deal Clears Antitrust Hurdle

Financial news for LGND dated on 2020-05-03: The Week Ahead In Biotech: Smid-Cap Earnings News Flow Picks Up Pace

Financial news for LGND dated on 2020-04-08: 10 Biggest Price Target Changes For Wednesday

Financial news for LGND dated on 2020-04-08: HC Wainwright & Co. Maintains Buy on Ligand Pharmaceuticals, Lowers Price Target to \$229

Financial news for LGND dated on 2020-03-24: Benzinga's Top Upgrades, Downgrades For March 24, 2020

Financial news for LGND dated on 2020-03-24: Argus Research Downgrades Ligand Pharmaceuticals to Hold

Financial news for LGND dated on 2020-03-18: The Daily Biotech Pulse: AbbVie, Allergan Agree On Divestments, Obalon Stops Obesity Balloon Sale, COVID-19 Updates

Financial news for LGND dated on 2020-03-12: Stocks That Hit 52-Week Lows On Thursday

Financial news for LGND dated on 2020-03-10: Guggenheim Securities Initiates Coverage On Ligand Pharmaceuticals with Neutral Rating

Financial news for LGND dated on 2020-02-27: 100 Stocks Moving In Thursday's Mid-Day Session

Financial news for LGND dated on 2020-02-27: UPDATE: Ligand Pharma Raises FY20 EPS Guidance From \$3.45 To \$3.62 vs \$3.47 Estimate, Sales From ~\$128M To ~\$133M vs \$125.8M Est.

Financial news for LGND dated on 2020-02-27: Ligand Pharma Raises FY20 Guidance, Cites Higher Captisol Material Sales

Financial news for LGND dated on 2020-02-11: Ligand Raises FY20 Adj. EPS Guidance From \$3.40 To \$3.45 vs \$3.44 Estimate

Financial news for LGND dated on 2020-02-11: Ligand Pharma Reports Purchase Of Core Assets, Partnered Programs, Ion Channel Technologies From Icagen For \$15M In Cash

Financial news for LGND dated on 2020-02-06: Ligand Pharmaceuticals Sees FY20 Sales Guidance Of \$121M Vs 124.49M Estimate; EPS \$3.40 Vs \$3.49 Estimate

Financial news for LGND dated on 2020-02-06: Ligand Pharmaceuticals Q4 EPS \$0.71 Beats \$0.61 Estimate, Sales \$27M Beat \$25.16M Estimate

Financial news for LGND dated on 2020-02-06: Benzinga's Top Upgrades, Downgrades For February 6, 2020

Financial news for LGND dated on 2020-02-06: The Daily Biotech Pulse: Tonix Slumps On Failed Study, Applied Genetic Announces Offering, Beam Therapeutics, PPD Price IPOs

Financial news for LGND dated on 2020-02-03: Ligand Pharmaceuticals Says Its Technologies Are 'being utilized by partners to support and enable potential treatments for the 2019 novel coronavirus'

Financial news for LGND dated on 2020-02-02: The Week Ahead In Biotech: Merck, Bristol-Myers Earnings, Conference Presentations In Focus

Financial news for LGND dated on 2020-01-13: Ligand Enters Into OmniAb Platform License Agreement With Pandion Therapeutics

Financial news for LGND dated on 2020-01-13: 25 Stocks Moving in Monday's Pre-Market Session

Financial news for LGND dated on 2019-12-06: 12 Biotech Stocks Primed For A Short Squeeze

Financial news for LGND dated on 2019-12-02: Ligand Announces the Licensing of its OmbniAb to Sanofi

Financial news for LGND dated on 2019-11-08: Ligand Presents Results From Phase 1 Clinical Trial Of Captisol-Enabled Iohexol At American Society Of Nephrology Kidney Week 2019

Financial news for LGND dated on 2019-11-05: Ligand Pharmaceuticals Cuts FY19 Adj. EPS Guidance From \$3.20 to \$3.00 vs \$3.25 Est.

Financial news for LGND dated on 2019-11-05: Ligand Reaffirms FY19 Sales Guidance \$118M vs \$119.71M Est.

Financial news for LGND dated on 2019-11-05: Ligand Pharmaceuticals Q3 EPS \$0.49 Misses \$0.61 Estimate, Sales \$24.8M Beat \$22.36M Estimate

Financial news for LGND dated on 2019-11-05: The Daily Biotech Pulse: FDA Nod For Sanofi, BioCryst's Edema Drug In Japan, Myriad's Q1 Disappointment

Financial news for LGND dated on 2019-11-03: The Week Ahead In Biotech: Smid-Cap Earnings Deluge, SITC Conference In The Spotlight

Financial news for LGND dated on 2019-10-25: The Daily Biotech Pulse: Melinta Crosses FDA Hurdle But Sees Liquidity Pushback, Positive Readout For Aclaris Wart Drug

Financial news for LGND dated on 2019-10-24: The Daily Biotech Pulse: Acorda To Trim Jobs, GlaxoSmithKline Gets FDA Nod, Edward Lifesciences Posts Q3 Beat-And-Raise

Financial news for LGND dated on 2019-10-20: The Week Ahead In Biotech: Earnings Trickle In, While Glaxo, Melinta, Foamix And Eton Await FDA Verdict

Financial news for LGND dated on 2019-09-30: Attention Biotech Investors: Mark Your Calendar For These October PDUFA Dates

Financial news for LGND dated on 2019-09-26: Shares of several healthcare companies are trading lower, potentially on recent Democratic primary polls showing Senator Elizabeth Warren in the lead.

Financial news for LGND dated on 2019-09-24: Shares of many pharma/therapeutics stocks trading lower in sympathy with overall market weakness. Reports China is planning to cut prices for widely-used drugs may also be pressuring the sector today.

Financial news for LGND dated on 2019-09-23: Ligand Pharmaceuticals Licensee Sermonix Doses First Patient In Phase 2 Clinical Trial Of Lasofoxifene For Targeted Precision Medicine Treatment Of Women With ESR1 Mutations In Metastatic Breast Cancer

Financial news for LGND dated on 2019-09-19: Benzinga's Top Upgrades, Downgrades For September 19, 2019

Financial news for LGND dated on 2019-09-19: 10 Biggest Price Target Changes For Thursday

Financial news for LGND dated on 2019-09-19: Barclays Upgrades Ligand Pharmaceuticals to Overweight, Raises Price Target to \$132

Financial news for LGND dated on 2019-09-12: Ligand Pharmaceuticals Says Recently Entered Into an Omniab Commercial Platform License Agreement With Hong Kong-based Kira Pharmaceuticals

Financial news for LGND dated on 2019-09-04: The Daily Biotech Pulse: Puma Leaps, Aerie Borrows, Hepion Back In Nasdaq's Good Books

Financial news for LGND dated on 2019-08-13: Shares of several healthcare companies are trading higher with the overall market after the U.S. announced it is excluding and delaying the additional 10% tariff on certain products.

Financial news for LGND dated on 2019-08-12: Ligand Pharma Reports Partnership With CASI Pharma To Launch EVOMELA in China

Financial news for LGND dated on 2019-08-06: The Daily Biotech Pulse: Sanofi's Dupixent Found Effective For Pediatric Itchy Skin, Novavax Gets Nod For Late-Stage Study, Allakos Offering

Financial news for LGND dated on 2019-08-05: New 52-Week Lows For Monday Morning

Financial news for LGND dated on 2019-08-05: Barclays Maintains Equal-Weight on Ligand Pharmaceuticals, Lowers Price Target to \$110

Financial news for LGND dated on 2019-08-01: The Daily Biotech Pulse: Exelixis Signs Cancer Drug Licensing Deal, Adamis Offering, Surmodics Surges On Earnings

Financial news for LGND dated on 2019-07-31: 80 Biggest Movers From Yesterday

Financial news for LGND dated on 2019-07-30: Long-Time Ligand Short Increases Position As Shares Fall 11% On Earnings

Financial news for LGND dated on 2019-07-30: 58 Stocks Moving In Tuesday's Mid-Day Session

Financial news for LGND dated on 2019-07-30: Ligand Pharmaceuticals: Lemelson Capital Management Announces That It Had Increased Its Short Position In Ligand Pharmaceuticals

Financial news for LGND dated on 2019-07-30: New 52-Week Lows for Tuesday Morning

Financial news for LGND dated on 2019-07-30: Ligand Pharmaceuticals Q2 EPS \$0.68 Beats \$0.55 Estimate, Sales \$24.99M Beat \$21.01M Estimate

Financial news for LGND dated on 2019-07-23: Ligand Pharma Reports Purchase Of Ab Initio Biotherapeutics For \$12M In Cash

Financial news for LGND dated on 2019-07-10: Ligand Announces Phase 1 Clinical Trial Of Captisol-enabled Iohexol Achieved Primary Endpoint

Financial news for LGND dated on 2019-07-08: Ligand And SQ Innovation Enter Into Exclusive Worldwide Captisol License And Supply Agreements For High-Concentration Furosemide Formulation

Financial news for LGND dated on 2019-07-03: Ligand Pharma Has Entered Into OmniAb Commercial Platform License, Services Deal With Takeda's Millennium

Financial news for LGND dated on 2019-07-01: Ligand Pharmaceuticals Highlights Launch Of Sage Therapeutics' ZULRESSO, Which Utilizes Ligand's Captisol

Financial news for LGND dated on 2019-06-12: Ligand Pharma Reports Subsidiary Vernalis And PhoreMost Report Drug Discovery Collaboration For Novel Oncology Target

Financial news for LGND dated on 2019-06-11: Barclays Initiates Coverage On Ligand Pharmaceuticals with Equal-Weight Rating, Announces \$131 Price Target

Financial news for LGND dated on 2019-06-04: Shares of several healthcare companies are trading higher with the overall US market. Recent comments out of China and Mexico has renewed trade optimism and lifted economic outlook.

Financial news for LGND dated on 2019-05-17: Ligand Pharma Reports Signed License Deal Granting Cumulus Oncology Exclusive Global Rights To Develop, Commercialize VER250840 Using Co.'s VDP System; Co. To Receive Upfront License Fee, Eligible For \$76M In Milestone Payments

Financial news for LGND dated on 2019-05-06: Ligand Reports Purchase Of Milestone, Royalty Rights To SB206 From Novan For \$12M, Will Be Entitled To Receive Tiered Royalty Of 7-10%, As Well As Up To \$20M In Regulatory, Commercial Milesontes

Financial news for LGND dated on 2019-05-03: The Daily Biotech Pulse: Obseva Reports Positive Endometriosis Drug Trial, Assembly Biosciences Execs Depart, Coherus Settles With Amgen

Financial news for LGND dated on 2019-05-02: Ligand Pharmaceuticals Reaffirms FY19 Revenue Guidance Of \$118M Which May Not Compare To The \$139.25M Estimate; Affirms FY19 Adj. EPS Guidance Of \$3.20 Which May Not Be Comparable To The \$4.16 Estimate

Financial news for LGND dated on 2019-05-02: Ligand Pharmaceuticals Q1 EPS \$1.16 Beats \$1.02 Estimate, Sales \$43.5M Beat \$39.79M Estimate

Financial news for LGND dated on 2019-05-02: Ligand Completes Enrollment Of Phase 1

## Clinical Trial Of Captisol-Enabled Iohexol

Financial news for LGND dated on 2019-05-02: The Daily Biotech Pulse: FDA Nod For Sanofi's Dengue Vaccine, Veracyte Offering, Biogen Reports Positive Data

Financial news for LGND dated on 2019-04-22: UPDATE: Ligand Says Will Receive Upfront Payment, Eligible To Receive Development, Commercial Milestone Payments, Royalties, No Terms Disclosed

Financial news for LGND dated on 2019-04-22: UPDATE: Ligand Says Will Be Able To Use OmniAb Platform Rodents, Birds In Campaigns To Discover Fully Human Mono-, Bispecific Antibodies

Financial news for LGND dated on 2019-04-22: Ligand Pharma 8-K Shows Co. Executed, Delivered On OmniAb Platform License Deal With A Bay-Area Venture-Stage Biotech Co.

Financial news for LGND dated on 2019-04-15: Ligand Reports 9.99% Stake in Seelos Therapeutics as of February 27

Financial news for LGND dated on 2019-04-11: The Daily Biotech Pulse: NASH Cheer For Intercept, Gilead Layoffs, BioDelivery Licenses Constipation Drug

Financial news for LGND dated on 2019-04-07: The Week Ahead In Biotech: Conferences, PDUFA Dates And Clinical Trial Readouts

Financial news for LGND dated on 2019-03-21: Ligand Pharma Reports Will Receive \$3M Milestone Payment Related To FDA Approval Of Sage Therapeutics' ZULRESSO Injection For Treatment Of PPD

Financial news for LGND dated on 2019-03-19: The Daily Biotech Pulse: FDA Nod For Roche And Amphastar, Milestone Payment Kicks In For Affimed

Financial news for LGND dated on 2019-03-16: The Week Ahead In Biotech: Conferences, PDUFA Dates, Clinical Trials And Earnings

Financial news for LGND dated on 2019-03-12: Ligand At Investor Day Affirmed FY19 Sales Guidance Of ~\$118M

Financial news for LGND dated on 2019-03-07: 58 Biggest Movers From Yesterday

Financial news for LGND dated on 2019-03-06: 45 Stocks Moving In Wednesday's Mid-Day Session

Financial news for LGND dated on 2019-03-06: Ligand Pharmaceuticals shares are trading lower after the company cut FY19 guidance and announced the sale of its Promacta assets and royalty for \$827 million.

Financial news for LGND dated on 2019-03-05: Ligand Adjusts FY19 Guidance: Sales ~\$118M, Adj. EPS \$32.25

Financial news for LGND dated on 2019-03-05: Ligand Pharma Reports Sale Of Promacta Assets, Royalty For \$827M

Financial news for LGND dated on 2019-03-04: Attention Biotech Investors: Mark Your Calendar For These March PDUFA Dates

Financial news for LGND dated on 2019-02-07: Ligand Raises FY19 Sales Guidance From ~\$212M To ~\$224M vs \$213M Estimate

Financial news for LGND dated on 2019-02-07: Ligand Pharmaceuticals Q4 EPS \$1.70 Beats \$1.18 Estimate, Sales \$59.6M Beat \$51.26M Estimate

Financial news for LGND dated on 2019-02-07: The Daily Biotech Pulse: Galapagos-Evotec Forge Fibrosis Partnership, Sanofi Earnings, Alektor To Debut

Financial news for LGND dated on 2019-02-07: Ligand Pharmaceuticals Says On Feb 4 Entered Into Worldwide Commercial Platform License Agreement With Genagon Therapeutics; Genagon Gained Access To Full Omniab Transgenic Animal Technology Platform; Ligand Eligible To Receive Milestone Payments, Tiered Royalties Of 4%-6% For Each Product Incorporating Omniab-derived Antibody

Financial news for LGND dated on 2019-02-03: The Week Ahead In Biotech: Conferences, Clinical Trials, Earnings And IPOs

Financial news for LGND dated on 2019-01-28: Ligand Pharma 8-K Shows Board Added \$150M To Buyback Plan

Financial news for LGND dated on 2019-01-25: Ligand Pharma Highlights Its Partner, Seelos Therapeutics, Closed The Merger With Apricus Biosciences And Will Be Publicly

Traded Under Nasdaq Symbol 'SEEL'

Financial news for LGND dated on 2019-01-17: The Daily Biotech Pulse: FDA Panel Backs Amgen's Hypertension Drug, Adamis Allergy Drug Launched In US

Financial news for LGND dated on 2019-01-17: 58 Biggest Movers From Yesterday

Financial news for LGND dated on 2019-01-16: Emmanuel Lemelson Issues Press Release Highlighting A Renewed Call For Probe In Alleged Accounting, Securities Fraud, SEC Failures At Ligand

Financial news for LGND dated on 2019-01-16: Ligand Pharmaceuticals Hit By Bearish Citron Report

Financial news for LGND dated on 2019-01-16: 'That's simply false. There are few pharma companies that disclose more information about their business in a fully transparent manner than \$LGND (2/4)' -Tweet From STAT's Adam Feuerstein

Financial news for LGND dated on 2019-01-16: '...on @CitronResearch \$LGND report. What I found most disappointing (and fundamentally dishonest) about Andrew's work is the accusation that \$LGND is lying to investors about its royalty-based business model (1/4)' -Tweet From STAT's Adam Feuerstein

Financial news for LGND dated on 2019-01-16: 'So, @CitronResearch short thesis on \$LGND boils down to \$VKTX needing to blow up. Alright, good luck, Andrew. If \$VKTX pans out, you're toast, but then, he'll probably be out by then. The rest of the report is un-readable.' -STAT's Adam Feuerstein

Financial news for LGND dated on 2019-01-16: Ligand Shares dip lower after shortseller Citron Research issued a bearish call on the stock, citing 'deception'.

Financial news for LGND dated on 2019-01-16: Ligand Shares Fall ~7% Following Citron Tweet Call Co. 'The Next Valeant'

Financial news for LGND dated on 2019-01-16: '\$LGND tgt \$35. Our most comprehensive piece of pharma research since Valeant. Citron exposes the deception behind \$LGND and details the truth of their pipeline with pictures and filings.' -Tweet From Citron Research

Financial news for LGND dated on 2018-12-20: Ligand Pharmaceuticals shares are trading up 3.6% after the company raised FY18 guidance.

Financial news for LGND dated on 2018-12-19: Ligand Pharmaceuticals shares are trading up after the company raised FY18 guidance.

Financial news for LGND dated on 2018-12-19: The Daily Biotech Pulse: Pfizer-Glaxo Set Up Consumer Health Care Venture, New Patent For Adamas

Financial news for LGND dated on 2018-12-18: Ligand Sees FY19 Sales At Least \$212M With Up To Added \$40M Of Potential Milestone, License Payments vs \$204M Estimate

Financial news for LGND dated on 2018-12-18: UPDATE: Ligand Pharmaceuticals Raises FY18 Adj. EPS From ~\$6.52 To \$6.63

Financial news for LGND dated on 2018-12-18: Ligand Raises Guidance

Financial news for LGND dated on 2018-12-18: The Daily Biotech Pulse: Puma Aces Late-Stage Trial, Chinese Cheer For FibroGen, J&J \$5B Buyback Plan

Financial news for LGND dated on 2018-12-17: Ligand Reports Purchase Of Milestone and Royalty Rights to PTX-022 from Palvella Therapeutics For \$10M

Financial news for LGND dated on 2018-12-10: Sermonix Pharma Issues Press Release Highlighting FDA Accepted Its Investigational New Drug Application For Ligand's Lasofoxifene; Will Begin Phase 2 Trial For Targeted Treatment of Women With ESR1 Mutations in Metastatic Breast Cancer

Financial news for LGND dated on 2018-11-21: Ligand Pharma Reports Partnership With iMetabolic Biopharma For Its OmniAb

Financial news for LGND dated on 2018-11-08: Ligand Raises FY18 Sales Guidance From \$232M As Of Aug. 6, 2018 To ~\$240M vs \$234.8M Estimate

Financial news for LGND dated on 2018-11-08: Ligand Pharmaceuticals Incorporated Q3 EPS \$1.32 Beats \$1.03 Estimate, Sales \$45.7M Beat \$41.82M Estimate; Raises Guidance

Financial news for LGND dated on 2018-11-08: The Daily Biotech Pulse: Nantkwest Reports Positive Cancer Vaccine Trial Results, Sarepta Offering

Financial news for LGND dated on 2018-11-04: The Week Ahead In Biotech: Earnings, Conferences, PDUFA Dates, Clinical Trial Results And IPOs

Financial news for LGND dated on 2018-10-30: S&P Dow Jones Indices Announces Keysight Technologies Set to Join S&P 500; Ligand Pharmaceuticals to Join S&P MidCap 400; Marcus & Millichap and Arcosa to Join S&P SmallCap 600

Financial news for LGND dated on 2018-10-02: Stocks Which Set New 52-Week High Yesterday, October 1st

Financial news for LGND dated on 2018-09-28: The Daily Biotech Pulse: FDA Nods For Adamis, Eli Lilly, Pfizer; Spero, Obseva Report Positive Trial Results

Financial news for LGND dated on 2018-09-26: Stocks Which Set New 52-Week High Yesterday, September 25th

Financial news for LGND dated on 2018-09-24: Ligand Pharmaceuticals Board Approves Up to \$200M Share Buyback

Financial news for LGND dated on 2018-09-19: 10 Biggest Price Target Changes For Wednesday

Financial news for LGND dated on 2018-09-19: The Daily Biotech Pulse: Johnson & Johnson's Generic Unit Files NDA For Urinary Tract Cancer Drug, GI Therapeutics Prices Offering

Financial news for LGND dated on 2018-09-19: H.C. Wainwright Maintains Buy on Ligand Pharmaceuticals, Raises Price Target to \$270

Financial news for LGND dated on 2018-09-12: Lemelson Capital's Fr. Emmanuel Lemelson Responds To Civil Complaint Filed Against Him Today by SEC Alleging Securities Law Violations Related To Trading Ligand Pharma, Says This Matter 'Has no merit...amounts to a gross abuse of prosecutorial discretion'

Financial news for LGND dated on 2018-09-04: Stocks Which Set New 52-Week High Friday, August 31

Financial news for LGND dated on 2018-08-31: Stocks Which Set New 52-Week High Yesterday, August 30th

Financial news for LGND dated on 2018-08-28: The Daily Biotech Pulse: Regulatory Roadblock For Akcea-Ionis, Affimed's Alliance, FDA Nod For Tetraphase's Antibiotic

Financial news for LGND dated on 2018-08-17: Goldman Sachs Initiates Coverage On Ligand Pharmaceuticals with Neutral Rating, Announces \$256 Price Target

Financial news for LGND dated on 2018-08-15: Stocks Which Set New 52-Week High Yesterday, August 14th

Financial news for LGND dated on 2018-08-09: Ligand Pharma Offers To Buy Vernalis For \$43M In Cash

Financial news for LGND dated on 2018-08-08: Roth Capital Likes Ligand, But Valuation Renders Shares 'Increasingly Speculative'

Financial news for LGND dated on 2018-08-08: Stocks Which Set New 52-Week High Yesterday, August 7th

Financial news for LGND dated on 2018-08-08: Benzinga's Top Upgrades, Downgrades For August 8, 2018

Financial news for LGND dated on 2018-08-08: The Daily Biotech Pulse: FDA Panel Backs Insmed, Eidos' Maiden Earnings, Paratek Awaits Adcom Verdict

Financial news for LGND dated on 2018-08-08: Roth Capital Downgrades Ligand Pharmaceuticals to Neutral

Financial news for LGND dated on 2018-08-07: The Daily Biotech Pulse: FDA Snub For Gemphire, Ligand Earnings, Insmed's Antibiotic Faces FDA Panel

Financial news for LGND dated on 2018-08-06: Ligand Pharmaceuticals Raises FY18 Sales Guidance From \$226M To \$232M vs \$216.58M Est.

Financial news for LGND dated on 2018-08-06: Ligand Pharmaceuticals Q2 Adj. EPS \$2.59 Beats \$2.34 Estimate, Sales \$90M Beat \$82.2M Estimate

Financial news for LGND dated on 2018-07-30: Apricus Biosciences, Inc. Announces Merger Agreement with Seelos Therapeutics In All-Stock Transaction; Apricus Shareholders To Own ~14% Of The Combined Co. With Seelos Owning ~86% Of The Combined

Co.

Financial news for LGND dated on 2018-07-20: Stocks Which Set New 52-Week High Yesterday

Financial news for LGND dated on 2018-07-20: Benzinga's Daily Biotech Pulse: PTC To Buy Agilis, Zynerba To Offer Shares, Intuitive Surgical's Strong Q2

Financial news for LGND dated on 2018-07-19: Benzinga's Daily Biotech Pulse: Novartis Licenses Skin Drug, 2 Stocks To Debut

Financial news for LGND dated on 2018-07-13: Benzinga's Daily Biotech Pulse: Amgen Resubmits Osteoporosis Drug BLA, Auris Medical Prices Offering

Financial news for LGND dated on 2018-06-29: Benzinga's Daily Biotech Pulse: Gemphire On Fire, Acceleron-Celgene Taste Success, AbbVie Ditches Galapagos

Financial news for LGND dated on 2018-06-27: Ligand Raises FY18 Sales Guidance From \$184M To \$226M vs \$188.2M Estimate

Financial news for LGND dated on 2018-06-27: Ligand Pharma Reports Received \$47M From WuXi Biologics For Expansion Of Global OmniAb Platform License Deal

Financial news for LGND dated on 2018-06-21: Benzinga's Top Upgrades, Downgrades For June 21, 2018

Financial news for LGND dated on 2018-06-21: Argus Initiates Coverage On Ligand Pharmaceuticals with Buy Rating, Announces \$260 Price Target

Financial news for LGND dated on 2018-06-06: Benzinga's Daily Biotech Pulse: Vascular Biogenics Soars On Positive Platform Data, Axovant Licenses Parkinson's Candidate

Financial news for LGND dated on 2018-05-17: Benzinga's Daily Biotech Pulse: ASCO Abstracts, Fibrocell, Ispen And More

Financial news for LGND dated on 2018-05-16: Benzinga's Daily Biotech Pulse: Verastem Uprooted On Stock Offering, Titan Pharma Earnings

Financial news for LGND dated on 2018-05-10: UPDATE: Ligand Pharma Will Receive Undisclosed Upfront Payment, Is Eligible To Receive Annual Platform Access Payments, Development, Regulatory Milestone Payments

Financial news for LGND dated on 2018-05-10: Ligand Pharmaceuticals Says Entered Commercial Platform License Agreement, With KSQ Therapeutics

Financial news for LGND dated on 2018-05-10: Ligand Pharma 8-K Shows Co. Entered Commercial Platform License Agreement With KSQ Under Which KSQ Will Be Able To Use Co.'s Full OmniAb Platform To Discover Antibodies

Financial news for LGND dated on 2018-05-08: Ligand Pharmaceuticals Q1 Adj. EPS \$1.55 Beats \$1.15 Estimate, Sales \$56.2M Beat \$42.69M Estimate

Financial news for LGND dated on 2018-05-08: Benzinga's Daily Biotech Pulse: Valeant Earnings, Lipocine's FDA Watch, Invivo CFO Departure

Financial news for LGND dated on 2018-05-06: The Week Ahead In Biotech: PDUFA Dates, Earnings, IPOs And More

Financial news for LGND dated on 2018-03-07: H.C. Wainwright Maintains Buy on Ligand Pharmaceuticals, Raises Price Target to \$182.00

Financial news for LGND dated on 2018-03-07: Ligand Pharmaceuticals Says Underreported Potential Aggregate Milestone Payments Related to License Agreement With Roivant Sciences for LGD-6972; Ligand Pharma to Receive Potential License & Milestone Payments Up to \$548.8M -8K

Financial news for LGND dated on 2018-03-06: Ligand Licenses Glucagon Receptor Antagonist Program to Roivant Sciences

Financial news for LGND dated on 2018-02-21: Ligand Pharma Sees FY18 Adj. EPS \$4.22 vs \$4.42 Est., Sales \$164M vs \$166.88M Est.

Financial news for LGND dated on 2018-02-21: Ligand Pharma Reports Q4 Adj. EPS \$1.31 vs \$1.14 Est., Sales \$50.5M vs \$47.82M Est.

Financial news for LGND dated on 2018-02-21: Ligand Pharmaceuticals Q4 Earnings Preview

Financial news for LGND dated on 2018-02-19: The Week Ahead In Biotech: Earnings,

## PDUFA Dates And More

Financial news for LGND dated on 2018-01-23: Ligand Pharma Shares Continue Higher Tues., Up 2%; Stock Up 19% YTD; Form 4 Filing Late Mon. From CEO John Higgins Showed Exercise Of ~16K Shares, Sale Of 11.85K Shares On Jan. 19

Financial news for LGND dated on 2018-01-22: Ligand Enters into Worldwide OmniAb Platform License Agreement with Ferring Pharmaceuticals

Financial news for LGND dated on 2018-01-18: Ligand Pharma Reports Established Program To Develop Captisol-Enabled, Next-Gen Contrast Agents For Diagnostic Imaging

Financial news for LGND dated on 2018-01-11: Ligand Pharma Reports Entered Into Global OmniAb Platform License Deal With Glenmark Pharma

Financial news for LGND dated on 2018-01-03: Ligand Pharma Reports Earned \$6M As OmniAb Partner Out-Licenses Antibody Projects

Financial news for LGND dated on 2017-11-21: 35 Biggest Movers From Yesterday

Financial news for LGND dated on 2017-11-20: Mid-Afternoon Market Update: Dow Gains 90 Points; Micronet Enertec Technologies Shares Drop

Financial news for LGND dated on 2017-11-20: 32 Stocks Moving In Monday's Mid-Day Session

Financial news for LGND dated on 2017-11-20: Mid-Day Market Update: Crude Oil Down 1%; Northern Technologies Shares Surge After Q4 Results

Financial news for LGND dated on 2017-11-20: Mid-Morning Market Update: Markets Open Higher; Marvell To Buy Cavium For \$6B

Financial news for LGND dated on 2017-11-20: Benzinga's Top Upgrades, Downgrades For November 20, 2017

Financial news for LGND dated on 2017-11-20: Deutsche Bank Downgrades Ligand Pharmaceuticals to Sell

Financial news for LGND dated on 2017-11-14: Ligand Pharmaceuticals Sees FY17 Adj. EPS \$2.95-\$3 vs \$2.95 Est., Sales \$134M-\$136M vs \$134.35M Est.

Financial news for LGND dated on 2017-11-14: Ligand Pharmaceuticals and Boingo Wireless Holding Analyst/Investor Days Today

Financial news for LGND dated on 2017-11-13: The Week Ahead For November 13: Conferences, Earnings and IPO Events To Watch

Financial news for LGND dated on 2017-11-13: Ligand Announces an Agreement to License its Captisol to Meridian Labs, Ligand Could Receive Payment from Licenses, Royalties or Milestone Payments

Financial news for LGND dated on 2017-11-09: Ligand Updates FY17 Outlook, Raises Adj. EPS From \$2.93 to \$2.95-\$3 vs \$2.95 Est., Sales From \$134M vs \$134M-\$136M vs \$134.55M Est.

Financial news for LGND dated on 2017-11-09: Ligand Pharma Reports Q3 Adj. EPS \$0.69 vs \$0.61 Est.

Financial news for LGND dated on 2017-11-09: H.C. Wainwright Maintains Buy on Ligand Pharmaceuticals, Raises Price Target to \$159.00

Financial news for LGND dated on 2017-10-04: Ligand Pharma Reports Purchase Of Crystal Bioscience For \$25M In Cash Plus added Potential Payments Of Up To \$10.5M

Financial news for LGND dated on 2017-09-06: Citi Biotech Conference Begins Today, Presenters Include: Gilead, Ligand, Puma Biotech, and Bioverativ

Financial news for LGND dated on 2017-09-05: Benzinga's Top Upgrades, Downgrades For September 5, 2017

Financial news for LGND dated on 2017-09-05: Analyst Makes The Case For Ligand As A 'Core' Holding

Financial news for LGND dated on 2017-09-05: Ligand Pharma Phase 2 Study of LGD-6972 Met Primary Endpoint

Financial news for LGND dated on 2017-09-05: H.C. Wainwright Assumes Ligand Pharmaceuticals at Buy, Announces price target \$150.00



Financial news for LGND dated on 2017-08-18: Ligand to Receive \$2M from WuXi Biologics for Licensing Clinical-Stage anti-PD-1 Antibody Discovered Using the OmniAb Technology

Financial news for LGND dated on 2017-08-07: Ligand Pharmaceuticals Reports Q2 Adj. EPS \$0.67 vs \$0.46 Est., Sales \$28M vs \$24.07M Est.

Financial news for LGND dated on 2017-07-17: Ligand Enters Into Commercial License, Supply Agreement with Amgen for Rights to Use Captisol in the Formulation of AMG 330

Financial news for LGND dated on 2017-07-05: Attention Biotech Investors: Keep Your Date With July PDUFA Action-Days

Financial news for LGND dated on 2017-06-20: Ligand Reports Melinta Therapeutics Received FDA Approval For Baxdeal For Acute Bacterial Skin, Skin Structure Infections

Financial news for LGND dated on 2017-06-08: Jefferies Health Care Conference Continues Today, Presenters Include: Ligand, Immunogen, TherapeuticsMD, Synergy Pharma, Ironwood, Acadia, Community Health Systems, & Celldex

Financial news for LGND dated on 2017-06-01: Ligand Enters into Worldwide OmniAb Platform License Agreement with Surface Oncology

Financial news for LGND dated on 2017-05-31: UPDATE: Ligand Announces, as Part of Royalty Rate Reduction, Aziyo Agreed to Pay Co. Up to \$10M of Added Sales-Based Milestones Tied to Commercial Success of Currently-Marketed Products

Financial news for LGND dated on 2017-05-31: Ligand Reports Received \$10M from Contractually Specified Royalty Rate Buy-Down Following Sale by CorMatrix

Financial news for LGND dated on 2017-05-31: Craig-Hallum Institutional Investor Conference Takes Place Today, Attendees Include: Auxilio, TrueCar, Ligand Pharma, 8x8, MACOM Technology, NetScout Systems

Financial news for LGND dated on 2017-05-30: Ligand Enters Into Worldwide OmniAb Platform License Agreement With xCella Biosciences

Financial news for LGND dated on 2017-05-30: Tracking The Busy June PDUFA Calendar

Financial news for LGND dated on 2017-05-25: Companies Holding Shareholder Meetings Today Include: Acadia Healthcare, Big Lots, Arconic, Axon Enterprise, AK Steel, Cinemark, Green Dot, Fitbit, Ligand Pharmaceuticals, Norwegian Cruise Line, Raytheon, & Tiffany

Financial news for LGND dated on 2017-05-23: 8-K from Ligand Pharma Shows Co. Entered License, Supply Deal with Analgesix Granting IAX Exclusive Right to Use Captisol in IAX's Development, Commercialization of Captisol-Enabled Version of Specified Compound

Financial news for LGND dated on 2017-05-09: Ligand Affirms FY17 Outlook: Core Sales of \$130M vs \$133.9M Est., Adj. EPS ~\$2.70 vs \$2.71 Est.

Financial news for LGND dated on 2017-05-09: Ligand Reports Q1 Adj. EPS \$0.57 vs \$0.63 Est., Sales \$29.3M vs \$31.2M Est.

Financial news for LGND dated on 2017-04-05: Ligand Enters Commercial License, Supply Agreements with Marinus Pharmaceuticals for Captisol-Enabled Ganaxolone

Financial news for LGND dated on 2017-03-28: Ligand Pharma Announces Licensing Partner Janssen Filed IND for Antibody Discovered Using OmniAb Technology, Results in \$1M Milestone Payment

Financial news for LGND dated on 2017-03-03: 8-K from Ligand Pharma Highlights Co. is Eligible to Receive \$1.6M Upon Initiation of Retrophin's Phase 3 Trial of Sparsentan, ~\$5.99M Upon Filing of NDA in FSGS, Potential Net Milestones of \$65M+ in the Future, 9% Net Royalties

Financial news for LGND dated on 2017-02-28: Ligand Expands License With Sermonix To Include Worldwide Rights For Oral Lasofoxifene

Financial news for LGND dated on 2017-02-28: Sermonix Pharmaceuticals Secures Worldwide Rights to Oral Lasofoxifene From Ligand Pharmaceuticals, Increasing From U.S., Japan

Financial news for LGND dated on 2017-02-28: Ligand Holding Analyst Day Today

Financial news for LGND dated on 2017-02-27: Roth Capital Reinstates Ligand Pharmaceuticals With Buy

Financial news for LGND dated on 2017-02-23: Ligand Reports Q4 Adj. EPS \$0.74 vs \$1.19 Est., Sales \$38.2M vs \$40.34M Est.

Financial news for LGND dated on 2017-01-18: Emmanuel Lemelson Responds to Ligand's After-Hours 8-K, Tells Benzinga Filing 'may be indicative of a significant and material impact on the financials and perhaps yet another significant restatement by the company'

Financial news for LGND dated on 2017-01-18: UPDATE: Ligand Says 'expects to recognize royalties on sales of products commercialized by its partners when those products are sold by the partner, rather than when such payments are reported to the Company'

Financial news for LGND dated on 2017-01-18: UPDATE: Ligand Says Expects Revenue Related to Captisol Material Sales to Remain Unchanged

Financial news for LGND dated on 2017-01-18: UPDATE: Ligand Says Anticipates FASB Standard Will Have Most Significant Impact Related to Co. 'accounting for revenues related to royalties, and contingent "milestone" based payments'

Financial news for LGND dated on 2017-01-18: UPDATE: Ligand Highlights FASB Accounting Standards Codification Topic 606 Must Be Adopted After Jan. 1, '17, No Later Than Jan. 1, '18; Says Standards Will Have Material Impact on Financial Statements

Financial news for LGND dated on 2017-01-18: Ligand Pharma Issues 8-K

Financial news for LGND dated on 2016-12-22: Ligand Reports Entering of Commercial License, Supply Deal for Captisol-Enabled Trametinib

Financial news for LGND dated on 2016-12-22: Ligand Enters License Agreemtn With Ono Pharmaceutical

Financial news for LGND dated on 2016-12-21: Lemelson On Ligand: Intrinsic Value Is Zero

Financial news for LGND dated on 2016-12-21: Rev. Emmanuel Lemelson Tells Benzinga Intrinsic Value on Ligand is \$0

Financial news for LGND dated on 2016-12-21: Lantern Foundation's Emmanuel Lamelson Issues Press Release on Ligand: 'Urges Senate Committee to Commence Investigation into Ligand'

Financial news for LGND dated on 2016-11-21: Ligand Partner Retrophin Reports Additional Positive Data from Phase 2 DUET Study of Sparsentan in Focal Segmental Glomerulosclerosis at ASN Kidney Week 2016

Financial news for LGND dated on 2016-11-09: Ligand Pharma Files for Non-Timely 10-Q

Financial news for LGND dated on 2016-11-03: Ligand Reports Q3 Adj EPS \$0.62 vs \$0.59 Est, Rev \$21.6M vs \$23.13M Est

Financial news for LGND dated on 2016-10-24: Ligand Pharma Announces Partner Melinta Therapeutics Submitted Baxdeal NDA for Hospital-Treated Skin Infections

Financial news for LGND dated on 2016-09-27: Ligand Pharmaceuticals -8% @\$103.85

Financial news for LGND dated on 2016-09-22: Ligand Reports Licensing of Four Programs to Seelos Therapeutics

Financial news for LGND dated on 2016-09-16: Ligand Reports OmniAb License Deal with TeneoBio

Financial news for LGND dated on 2016-09-13: Ligand Reports Initiation of Phase 2 Trial with LGD-6972 in Type 2 Diabetes

Financial news for LGND dated on 2016-09-12: Martin Shkreli on Ligand Valuation: Stock 'Doesn't Look Cheap, But I Don't Know If I'd Run Out and Short It'

Financial news for LGND dated on 2016-09-12: Martin Shkreli on Pharma Co./Stock Valuation: Discussing Ligand, Thinks Mgmt 'Runs a Really Good Co.,' But Highlights There is Always a Chance for a Discrepancy with Co. and Stock Valuation

Financial news for LGND dated on 2016-09-07: 18 Biggest Mid-Day Gainers For Wednesday

Financial news for LGND dated on 2016-09-07: Retrophin Up 40% On Kidney Disease Drug Trial, Shkreli Still Wants His \$25+ Million 'Hogan Reward'

Financial news for LGND dated on 2016-09-07: Benzinga's Top Upgrades

Financial news for LGND dated on 2016-09-07: The Market In 5 Minutes: All Eyes On Apple's New iPhone And Ackman's New Chipotle Stake

Financial news for LGND dated on 2016-09-07: Deutsche Bank Upgrades Ligand Pharmaceuticals to Hold

Financial news for LGND dated on 2016-08-24: Rough Month: A Closer Look At Ligand's Fall From All-Time Highs

Financial news for LGND dated on 2016-08-24: Technical Alert: Sellers Flood Ligand Pharmaceuticals In Sympathy With Mylan Labs Decline

Financial news for LGND dated on 2016-08-24: Downside in Ligand Pharma Shares Intensifies as \$106 Level Breached, Stock Down 3.2% for Session; Traders May Be Viewing Stock as Sympathy Play on Mylan Drug Price Increase Debate

Financial news for LGND dated on 2016-08-17: Ligand Down 20% Since August 1; What's The Street Thinking?

Financial news for LGND dated on 2016-08-17: Technical Alert: Horrible August For Ligand Pharmaceuticals Continues

Financial news for LGND dated on 2016-08-15: Ligand Pharma Reports Results from Phase 1 Trials with Co.'s LGD-6972 in Type 2 Diabetes Mellitus Published in Paper: Showed Favorable Safety, Tolerability, Pharmacokinetics, Improved Glycemic Response

Financial news for LGND dated on 2016-08-11: Ligand Pharmaceuticals Still Offers Double-Digits Upside, Vetr Crowd Says

Financial news for LGND dated on 2016-08-05: Deutsche Downgrades Ligand As Risk/Reward Becomes Challenging

Financial news for LGND dated on 2016-08-05: Deutsche Bank Downgrades Ligand Pharmaceuticals to Sell

Financial news for LGND dated on 2016-08-04: Ligand Affirms FY16 Outlook: Adj EPS \$3.41-\$3.46 vs \$3.30 Est., Sales \$115M-\$119M vs \$116M Est.

Financial news for LGND dated on 2016-08-04: Ligand Reports Q2 Adj. EPS \$0.50 vs \$0.40 Est., Sales \$19.5M vs \$18M Est.

Financial news for LGND dated on 2016-07-29: Ligand Reports Multi-Program LTP Technology Licensing Agreement with Nucorion Pharmaceuticals

Financial news for LGND dated on 2016-07-12: Adam Feuerstein Tweets '\$LGND -- derivative play off \$SAGE data. Captisol is used to soluble '547.'

Financial news for LGND dated on 2016-07-08: Ligand Reaches OmniAb Platform License Agreement with Gilead

Financial news for LGND dated on 2016-07-08: Ligand Enters into OmniAb Platform License Agreement with Gilead Sciences

Financial news for LGND dated on 2016-06-30: Ligand Receives \$4 Million from Expansion of Two OmniAb License Agreements, Sees Q2 Rev. Of \$19M vs. Est. \$18.12M

Financial news for LGND dated on 2016-06-30: Ligand Pharma Shares Giving Back Some of Last Three Day's Rally; Had Rallied ~8.7% This Week, Down ~2.6% Thurs.

Financial news for LGND dated on 2016-05-04: Ligand Pharmaceuticals Q1 Adjusted Earnings Beat

Financial news for LGND dated on 2016-05-04: Ligand Sees FY16 Adj. EPS \$3.41-\$3.46 vs \$3.37 Est., Sales \$115M-\$119M vs \$118.5M Est.

Financial news for LGND dated on 2016-05-04: Ligand Pharma Reports Q1 Adj. EPS \$0.97 vs \$0.67 Est., Sales \$29.6M vs \$26.5M Est.

Financial news for LGND dated on 2016-05-04: Ligand Pharma Announces Synthetic Rights from CoreMatrix for \$17.5M

Financial news for LGND dated on 2016-04-22: Roth Capital Reiterates \$147 Price Target & Buy Rating And Recommends Steady Accumulation Of Shares

Financial news for LGND dated on 2016-04-22: UPDATE: Under Original FDA Submission by Lundbeck in 2014, Ligand was to Earn a \$200K Milestone Payment

Financial news for LGND dated on 2016-04-22: FDA Accepts Lundbeck Resubmission of NDA

for Carnexiv (Carbamazepine)

Financial news for LGND dated on 2016-04-14: Viking Therapeutics Issues 960K Shares and a Warrant for 960K Shares to Ligand Pharma Per Previous Loan Agreement

Financial news for LGND dated on 2016-04-13: Stephens Calls Ligand 'Unique,' Sees \$150/Share Coming By 2017

Financial news for LGND dated on 2016-04-13: Stephens & Co. Initiates Coverage on Ligand Pharmaceuticals at Overweight, Announces \$150.00 PT

Financial news for LGND dated on 2016-04-07: Analyst Says Viking Therapeutics Can Quadruple Because Of Its Relationship With Ligand Scientists

Financial news for LGND dated on 2016-04-07: Ligand Partner Novartis Gets Key E.U. Approval: Roth Capital Likes It

Financial news for LGND dated on 2016-04-07: Ligand Pharma Announces Revolade Approved in US as First-in-Class Therapy for Children 1+ with Chronic ITP

Financial news for LGND dated on 2016-03-28: Ligand Pharma Reports Entered Into OmniAb Platform License Deal with ABBA Therapeutics

Financial news for LGND dated on 2016-03-28: Ligand Enters Into OmniAb Platform License Agreement With ABBA Therapeutics

Financial news for LGND dated on 2016-03-15: Ligand Partner Spectrum Pharmaceuticals Receives FDA Approval of EVOMELA for Injection, Will Receive \$6M Milestone

Financial news for LGND dated on 2016-03-11: Roth Capital Maintains Buy on Ligand Pharmaceuticals, Raises PT to \$147.00

Financial news for LGND dated on 2016-03-03: Benzinga's Top Initiations

Financial news for LGND dated on 2016-03-03: Buy Ligand Shares; HC Wainwright Sets \$146 Price Target

Financial news for LGND dated on 2016-03-03: HC Wainwright Says Ligand 'is all about sustainable revenues and earnings growth', Calls OmniAb Acquisition 'transformative for Ligand'

Financial news for LGND dated on 2016-03-03: H.C. Wainwright Initiates Coverage on Ligand Pharmaceuticals at Buy, Announces \$146.00 PT

Financial news for LGND dated on 2016-02-10: Ligand Reports Q4 EPS \$0.66 vs. Est. \$0.65, Rev. \$21.2M vs. Est. \$24.97M

Financial news for LGND dated on 2016-02-02: Ligand Pharma, Tizona Therapeutics Enter Platform License Agreement

Financial news for LGND dated on 2016-01-13: Ligand Reports OmniAb Platform Licensing Deal with Emergent BioSolutions

Financial news for LGND dated on 2016-01-08: Filing from Ligand Pharma Shows Registration for ~\$180.066M Offering of Common Stock via Selling Holders

Financial news for LGND dated on 2015-12-31: Roth Capital's Joseph Pantginis Reiterates Buy on Ligand Following Captisol Supply Deal with Gilead; 'We believe Ligand is strongly positioned for continued growth.'

Financial news for LGND dated on 2015-12-31: 8-K from Ligand Pharma Shows Co. Entered Supply Deal with Gilead for Captisol

Financial news for LGND dated on 2015-12-17: Shares of Ligand Pharma to Resume Trade at 4:30 p.m. EST

Financial news for LGND dated on 2015-12-17: UPDATE: Ligand Acquisition Of OMT Expected To Be Accretive To Rev. And Adj. EPS

Financial news for LGND dated on 2015-12-17: UPDATE: Ligand Deal To Be \$92.6M Cash, \$85.4M Ligand Common Stock

Financial news for LGND dated on 2015-12-17: Ligand To Acquire OMT For \$178M Cash & Stock

Financial news for LGND dated on 2015-12-08: Ligand Pharma, RODES Report Signing of Exclusive Captisol Licensing Deal for Three Programs

Financial news for LGND dated on 2015-11-18: UPDATE: Ligand Highlights 'Upwards of

\$1.8B in Partner R&D to Be Spent' on 125+ Programs, 72+ Cos.

Financial news for LGND dated on 2015-11-18: Ligand Sees FY16 Rev. \$107-\$111M vs. Est. \$107.4M, EPS \$3.33-\$3.38 vs. Est. \$3.15

Financial news for LGND dated on 2015-11-18: Ligand Sees FY17 Rev. Greater Than \$146M, Adj. EPS Greater Than \$4.75/Share

Financial news for LGND dated on 2015-11-18: Ligand Sees FY12-FY17 Sales Growth on CAGR Basis 36%, Adj. EPS 79%

Financial news for LGND dated on 2015-11-09: Ligand Sees FY15 Adj. EPS \$3.34-\$3.37 vs \$3.52 Est., Sales \$75M-\$76M vs \$82.4M Est.

Financial news for LGND dated on 2015-11-09: Ligand Sees Q4 Adj. EPS \$0.63-\$0.66 vs \$0.95 Est., Sales \$24.3M-\$25.3M vs \$31.6M Est.

Financial news for LGND dated on 2015-11-09: Ligand Pharma Reports Q3 Adj. EPS \$0.56 vs \$0.42 Est., Sales \$17.7M vs \$17.8M Est.

Financial news for LGND dated on 2015-10-23: Spectrum Pharmaceuticals Receives CRL from FDA for EVOMELA for Injection

Financial news for LGND dated on 2015-09-29: Ligand Expands Captisol License and Supply Agreements with SAGE Therapeutics to Include SAGE-689

Financial news for LGND dated on 2015-09-16: 8-K from Ligand Pharma Shows Board Approved \$200M Buyback Plan

Financial news for LGND dated on 2015-09-02: Revolade Gets EU Approval as First-in-Class Therapy for Patients with Severe Aplastic Anemia

Financial news for LGND dated on 2015-08-24: FDA Increases Use of Promacta to Include Treatment of Children Ages 1 and Older with Chronic Immune Thrombocytopenia

Financial news for LGND dated on 2015-08-04: Ligand Affirms FY15 Outlook

Financial news for LGND dated on 2015-08-04: Ligand Pharma Reports Q2 Adj. EPS \$1.81, Sales \$18.4M vs \$17M Est.

Financial news for LGND dated on 2015-07-30: Ligand Pharma Announces Entering Into of Commercial Licensing, Supply Deal with Sanofi for Capitsol-Enabled SAR-125844

Financial news for LGND dated on 2015-07-29: Roth Capital Analyst Squares Up Against Hedge Fund In Ligand Pharma

Financial news for LGND dated on 2015-07-24: Revolade Recommended by CHMP for EU Approval to Treat Patients with Severe Aplastic Anemia, a Serious Blood Disorder

Financial news for LGND dated on 2015-06-19: Cantor Boosts Ligand Pharma Target To \$93

Financial news for LGND dated on 2015-06-15: Deutsche Bank Cuts Ligand Pharma To Hold

Financial news for LGND dated on 2015-06-15: Benzinga's Top Downgrades

Financial news for LGND dated on 2015-06-15: Deutsche Bank Downgrades Ligand Pharmaceuticals To Hold

Financial news for LGND dated on 2015-06-15: Deutsche Bank Downgrades Ligand Pharmaceuticals to Hold

Financial news for LGND dated on 2015-06-12: FDA Approves Promacta(r) for New Pediatric Chronic Immune Thrombocytopenia (cITP) Indication

Financial news for LGND dated on 2015-06-07: Ligand Announces Favorable Results From Phase 1b Trial With LGD-6972 in Type 2 Diabetes

Financial news for LGND dated on 2015-06-07: Lemelson Doubles Short Position In Ligand Pharmaceuticals, Says It's Created 'Pyramid Scheme Of Shell Companies'

Financial news for LGND dated on 2015-06-02: UPDATE: Ligand Adjusts FY15 EPS Guidance from \$2.14-\$2.18 Previously to \$3.45-\$3.50 (Which Accounts for Viking IPO)

Financial news for LGND dated on 2015-06-02: UPDATE: Ligand Sees \$28.2M of Non-Operating Income During Q2 Related to 'Gain on Deconsolidation' from Viking IPO; Affirms Q2, FY15 Sales Guidance, Adjusts EPS Outlook

Financial news for LGND dated on 2015-06-02: Ligand Offers Update on Impact of Viking

## Therapeutics IPO, Updates FY15 Outlook

Financial news for LGND dated on 2015-05-11: Ligand Pharma Reports Q1 GAAP EPS \$0.04, Adj. EPS \$0.33 vs \$0.27 Est., Sales \$14.6M vs \$13.5M Est.; Sees Q2 Sales \$17M-\$17.5M vs \$16.4M Est.

Financial news for LGND dated on 2015-05-11: Ligand Acquires Rights to More Than 15 Development Programs from Selexis SA

Financial news for LGND dated on 2015-05-05: Ligand Partner Viking Therapeutics Announces Closing of Initial Public Offering, 3M Shares @ \$8/Shr

Financial news for LGND dated on 2015-04-29: Ligand Partner Viking Therapeutics Announces Pricing of 3M Shares At \$8.00/Share

Financial news for LGND dated on 2015-04-23: Ligand Pharma Names Melanie Herman as Interim CFO

Financial news for LGND dated on 2015-04-22: Ligand Pharma Earns \$500K Milestone From SAGE Therapeutics By Start Of Phase 3 Clinical Program For SAGE-547

Financial news for LGND dated on 2015-04-20: Ligand Announces Partner TG Therapeutics Shows Positive Pre-Clinical Data on IRAK4 Compounds

Financial news for LGND dated on 2015-04-10: Ligand Pharma, Metabasis Therapeutics Entered Into Amended Master License Agreement With Viking Therapeutics

Financial news for LGND dated on 2015-03-30: Spectrum Pharmaceuticals Says Evomela Stability Shown to be Significantly Longer Than Current Melphalan HCL for Injection

Financial news for LGND dated on 2015-03-09: Spectrum Pharmaceuticals Announces FDA Accepts NDA Filing for Captisol-Enabled Melphalan

Financial news for LGND dated on 2015-03-03: CRT Capital Initiates Ligand Pharmaceuticals With Buy

Financial news for LGND dated on 2015-03-03: Benzinga's Top Initiations

Financial news for LGND dated on 2015-03-03: CRT Capital Initiates Coverage on Ligand Pharmaceuticals at Buy, Announces \$102.00 PT

Financial news for LGND dated on 2015-02-12: Spectrum Pharmaceuticals Highlights Clinical Data for Captisol-Enabled Melphalan at 2015 BMT Tandem Meeting

Financial news for LGND dated on 2015-02-09: What's GlaxoSmithKline Doing In The E.U.?

Financial news for LGND dated on 2015-02-09: Ligand Pharmaceuticals Sees FY2017 Sales \$146.0M

Financial news for LGND dated on 2015-02-09: Ligand Pharmaceuticals Sees FY2016 Sales \$107.0M

Financial news for LGND dated on 2015-02-09: Morning Market Losers

Financial news for LGND dated on 2015-02-09: UPDATE: Ligand Pharmaceuticals Posts In-Line Q4 Earnings, Issues Weak Outlook

Financial news for LGND dated on 2015-02-09: Ligand Pharma Reports Q4 Adj. EPS \$0.60, Inline; Sees Q1 Adj. EPS \$0.25-\$0.27, Sales \$13M-\$13.5M; Reaffirms FY Outlook

Financial news for LGND dated on 2015-02-09: Earnings Scheduled For February 9, 2015

Financial news for LGND dated on 2015-02-06: Should Ligand Pharmaceuticals Worry Investors?

Financial news for LGND dated on 2015-02-03: Ligand Signs License Agreement With Sermonix for Lasofoxifene

Financial news for LGND dated on 2015-02-02: Ligand Promotes Matthew W. Foehr to President

Financial news for LGND dated on 2015-01-27: Tech Stock Strategist Sean Udall's Take On Apple's Earnings Report

Financial news for LGND dated on 2015-01-12: #Premarket Prep Technical Update - Apple Lower

Financial news for LGND dated on 2015-01-09: Retrophin Receives Orphan Drug

## Designation For Sparsentan

Financial news for LGND dated on 2015-01-08: Ligand Partner Melinta Therapeutics Reports Positive Phase 3 Results For Delafloxacin IV

Financial news for LGND dated on 2014-12-26: Spectrum Pharmaceuticals Files NDA with the FDA for Captisol-Enabled Melphalan

Financial news for LGND dated on 2014-12-22: Ligand Partner GlaxoSmithKline Announces US Regulatory Submission Seeking Additional Indication For Promacta

Financial news for LGND dated on 2014-12-19: Pfizer Receives EU Marketing Authorization for DUAVIVE; Ligan Entitled to Milestone Payment Following Pfizer Obtaining Pricing of DUAVIVE in Major European Market

Financial news for LGND dated on 2014-12-02: UPDATE: Deutsche Bank Initiates Coverage On Ligand Pharmaceuticals On Growing Royalty Play On Biopharma

Financial news for LGND dated on 2014-12-02: Deutsche Bank Initiates Coverage on Ligand Pharmaceuticals Incorporated at Buy, Announces \$74.00 PT

Financial news for LGND dated on 2014-11-19: Hedge Fund Guru Emmanuel Lemelson Just Revealed How He's Trading Apple (And 3 Other Stocks)

Financial news for LGND dated on 2014-11-18: Lemelson Capital Management CIO Discusses Ligand Pharmaceuticals Prior To Company Issuing Weak Guidance

Financial news for LGND dated on 2014-11-18: Ligand Release Offers Highlights from Analyst Day: Expecting FY15 Sales in \$81-\$83M Range vs \$91.9M Est., Sees FY16 Sales Exceeding \$107M, Adj. EPS Exceeding \$3.20, Sees FY17 Sales Exceeding \$146M, Adj. EPS Exceeding \$4.65

Financial news for LGND dated on 2014-11-18: From 8-K: Ligand Pharmaceuticals Incorporated Sees FY2015 EPS \$2.14-2.18 vs \$2.42 Est

Financial news for LGND dated on 2014-11-12: Ligand Reports Partner GSK Has EU Regulatory Submission for Severe Aplastic Anemia Indication for Revolade

Financial news for LGND dated on 2014-10-27: UPDATE: Ligand Pharmaceuticals Q3 Earnings Beat Street View

Financial news for LGND dated on 2014-10-27: Ligand Pharmaceuticals Incorporated Sees FY2014 EPS \$1.50-1.55 vs \$1.54 Est; Sees Sales \$64.0M-66.0M vs \$64.60M Est

Financial news for LGND dated on 2014-10-27: Ligand Pharmaceuticals Incorporated Sees Q4 EPS \$0.57-0.62; Sees Sales \$22.50M-24.50M

Financial news for LGND dated on 2014-10-27: Ligand Pharmaceuticals Incorporated Reports Q3 EPS of \$0.36 vs \$0.31 Est; Revenue of \$15.0M vs \$14.56M Est

Financial news for LGND dated on 2014-10-17: Why Lemelson Capital Is Short On Ligand Pharmaceuticals

Financial news for LGND dated on 2014-10-08: Dow Surges Over 200 Points After FOMC Minutes; Blackhawk Shares Jump On Strong Results

Financial news for LGND dated on 2014-10-08: Interface Drops On Q3 Warning; Symantec Shares Rise

Financial news for LGND dated on 2014-10-08: Ligand Pharmaceuticals Inc. Shares Gain On Q3 Pre-Announcement

Financial news for LGND dated on 2014-10-08: Mid-Morning Market Update: Markets Mostly Flat; Costco Posts Upbeat Earnings

Financial news for LGND dated on 2014-10-08: Morning Market Movers

Financial news for LGND dated on 2014-10-08: Ligand Pharmaceuticals Incorporated Sees FY2014 EPS \$1.50-1.55 vs \$1.55 Est; Sees Sales \$64.0M-66.0M vs \$64.20M Est

Financial news for LGND dated on 2014-10-08: Ligand Pharmaceuticals Incorporated Sees Q4 Sales \$22.50M-24.50M vs \$23.50M Est

Financial news for LGND dated on 2014-10-08: Ligand Pharmaceuticals Incorporated Raises Q3 EPS Guidance from \$0.26-0.29 to \$0.33-0.37 vs \$0.32 Est; Raises Q3 Sales Guidance from \$13.0M-14.0M to \$15.0M vs \$14.20M Est

Financial news for LGND dated on 2014-09-26: Ligand Earns \$550K Milestone Payment Triggered by EU Approval of Merck's Captisol-enabled NOXAFIL

Financial news for LGND dated on 2014-09-09: Ligand Licenses Captisol-Enabled Lamotrigine to CURx Pharma, Will Receive \$22M in Potential Milestone Payments

Financial news for LGND dated on 2014-08-27: Ligand Announces Partner GlaxoSmithKline Has Received FDA Approval for Promacta/Revolade

Financial news for LGND dated on 2014-08-25: Lemelson Capital Comments On Ligand Debt Offering

Financial news for LGND dated on 2014-08-15: UPDATE: Avion Pharma Reports Signing of Commercial License Deal with Ligand Pharma for Development, Commercialization of Four Captisol-Enabled Programs, Ligand Entitled to Upfront Payment

Financial news for LGND dated on 2014-08-15: Avion Pharma Reports Signing of Commercial License Deal with Ligand Pharma for Development, Commercialization of Four Captisol-Enabled Programs, Ligand Entitled to Upfront Payment

Financial news for LGND dated on 2014-08-14: Lemelson Capital Issues Report 'Ligand Pharma's \$225M Debt Issuance Solidifies Company's Insolvency, Substantially Raises Specter of Bankruptcy'

Financial news for LGND dated on 2014-08-14: Ligand Pharma Reports Signing of Multi-Program Captisol License Deal with Avion Pharma

Financial news for LGND dated on 2014-08-12: Marinus Pharma Announces Collaboration with Division of Ligand For Clinical Use of Captisol

Financial news for LGND dated on 2014-08-12: Stocks To Watch For August 12, 2014

Financial news for LGND dated on 2014-08-11: Ligand Pharma Reports \$225M Offering of Convertible Senior Notes, \$200M Buyback Plan

Financial news for LGND dated on 2014-08-07: Exclusive: Emmanuel Lemelson Talks Ligand Pharmaceuticals

Financial news for LGND dated on 2014-08-04: Ligand Pharmaceuticals Reports Earnings; Lemelson Capital Adds To Short Position

Financial news for LGND dated on 2014-08-04: Lemelson Capital Management Says Has Further Increased Short Position in Ligand Pharmaceuticals

Financial news for LGND dated on 2014-08-04: Ligand Pharmaceuticals Incorporated Sees Q3 EPS \$0.26-0.29; Sees Sales \$13.0M-14.0M vs \$17.0M Est

Financial news for LGND dated on 2014-08-04: Ligand Pharmaceuticals Incorporated Raises FY2014 EPS Guidance from \$1.40-1.45 to \$1.50-1.55 vs \$1.44 Est; Sees Sales \$64.0M-66.0M vs \$63.0M Est

Financial news for LGND dated on 2014-08-04: Ligand Pharmaceuticals Incorporated Reports Q2 EPS of \$0.24 vs \$0.14 Est; Revenue of \$10.61M vs \$9.67M Est

Financial news for LGND dated on 2014-08-04: Earnings Scheduled For August 4, 2014

Financial news for LGND dated on 2014-07-31: Option Alert: Sep \$60 Call; 2,000 Contracts Traded vs 74 OI; Currently \$50.20

Financial news for LGND dated on 2014-07-22: Ligand's SAGE Therapeutics Announces SAGE-547 Received Fast Track Designation to Treat Status Epilepticus

Financial news for LGND dated on 2014-07-22: Empire Asset Management Initiates Coverage on Ligand Pharmaceuticals Incorporated at Sell, Announces \$16.00 PT

Financial news for LGND dated on 2014-07-22: Empire Asset Management Initiates Coverage on Ligand Pharmaceuticals Incorporated at Sell, Announces \$16.00 PT

Financial news for LGND dated on 2014-07-17: Ligand Announces \$10M Buyback

Financial news for LGND dated on 2014-07-17: Ligand Pharmaceuticals Incorporated Raises Q2 Sales Guidance from \$9.0M-9.50M to \$10.60M

Financial news for LGND dated on 2014-07-16: Fed Says Districts Were Optimistic On Economic Outlook; Yahoo! Falls On Downbeat Results

Financial news for LGND dated on 2014-07-16: Yahoo Falls On Downbeat Results; Time Warner Shares Spike Higher

Financial news for LGND dated on 2014-06-25: Ligan Partner Announces Start of Phase 3 Eltrombopag



Financial news for LGND dated on 2014-06-24: Benzinga's Volume Movers

Financial news for LGND dated on 2014-06-24: TG Therapeutics Completes Licensing Agreement With Ligand Pharma to Develop Inhibitors of IRAK4

Financial news for LGND dated on 2014-06-24: Ligand Signs License Agreement with TG Therapeutics for IRAK-4 Inhibitor Program

Financial news for LGND dated on 2014-06-23: Ligand to Present Positive Data from Phase 1 Study of Effect of SERN Lasofoxifene

Financial news for LGND dated on 2014-06-17: Shares Of Ligand Follow Parabolic Curve Amid Responses Surrounding Promacta's Phase III Trial

Financial news for LGND dated on 2014-06-16: Shares of Ligand Pharma Tick Lower Following Word from Lemelson Capital Fund Has Initiated Short Position in Stock

Financial news for LGND dated on 2014-06-16: Ligand Announces Successful Phase 1 Trial For LGN-6972

Financial news for LGND dated on 2014-06-13: Ligand Announces Glaxo Has Presented Results from Phase 3 PETIT2 Study on Eltrombopag, Met Primary Endpoint

Financial news for LGND dated on 2014-05-22: Ligand Pharmaceuticals Licenses Five Programs to Viking Therapeutics, Extends \$2.5M Loan Facility

Financial news for LGND dated on 2014-05-14: UPDATE: Ligand Signs Research and Licensing Agreement with Omthera Pharmaceuticals for Dyslipidemia-related Diseases

Financial news for LGND dated on 2014-05-14: Ligand Enters into Research and License Agreement with Omthera Pharmaceuticals, a Wholly-owned Subsidiary of AstraZeneca -8-K

Financial news for LGND dated on 2014-05-12: UPDATE: Ligand Pharma Announces Milestone from Sage Therapeutics for SAGE-547

Financial news for LGND dated on 2014-05-12: Ligand Pharma Announces Milestone from Sage Therapeutics for SAGE-547

Financial news for LGND dated on 2014-05-07: Ligand Pharmaceuticals Incorporated Reports Q1 EPS of \$0.35 vs \$0.25 Est; Revenue of \$16.0M vs \$13.63M Est

Financial news for LGND dated on 2014-04-23: Spectrum Pharmaceuticals' Pivotal Trial of Captisol-Enabled (Propylene Glycol-Free) Melphalan Meets Primary Endpoint

Financial news for LGND dated on 2014-03-24: Brinson Patrick Initiates Coverage on Ligand Pharmaceuticals Incorporated at Outperform, Announces \$98.00 PT

Financial news for LGND dated on 2014-03-17: Ligand Pharma Announces \$1M Milestone Payment Triggered Following FDA Approval of Merck's Noxafil

Financial news for LGND dated on 2014-03-10: UPDATE: Captisol Licensee Lundbeck Announces FDA Acceptance of NDA Submission for Carbamazepine IV

Financial news for LGND dated on 2014-02-13: UPDATE: MLV & Co Reiterates on Ligand Pharmaceuticals Following Strong 4Q Report

Financial news for LGND dated on 2014-02-13: McNicoll Lewis Vlak Maintains Buy on Ligand Pharmaceuticals Incorporated, Raises PT to \$96.00

Financial news for LGND dated on 2014-02-11: Ligand Pharmaceuticals Incorporated Sees Q1 EPS \$0.22-0.25

Financial news for LGND dated on 2014-02-11: Ligand Pharmaceuticals Incorporated Reports Q4 EPS of \$0.35 vs \$0.19 Est; Revenue of \$14.70M vs \$14.25M Est

Financial news for LGND dated on 2014-02-10: Ligand to Receive \$1M Kyprolis Commercial Milestone Payment from Onyx Pharmaceuticals

Financial news for LGND dated on 2014-02-03: Roth Says Use of New Promacta May Provide 'Meaningful' Royalties, EPS Growth to Ligand

Financial news for LGND dated on 2014-02-03: Ligand Partner GlaxoSmithKline Receives FDA Breakthrough Therapy Designation for Promacta/Revolade for Severe Aplastic Anemia

Financial news for LGND dated on 2013-12-10: UPDATE: Cantor Fitzgerald Raises PT on Ligand Pharmaceuticals as Key Partnered Program Advances

Financial news for LGND dated on 2013-12-09: Ligand Announces Positive Preclinical

Data on Small-Molecule G-CSF Receptor Agonist at ASH

Financial news for LGND dated on 2013-12-04: Ligand Pharmaceuticals Sees FY 2013 Non-GAAP EPS from Continuing Operations per Diluted Share \$0.86-\$0.87 vs \$0.77-\$0.79

Financial news for LGND dated on 2013-12-04: Ligand Pharmaceuticals Sees Q4 EPS \$0.31-\$0.32 vs \$0.22-\$0.24; Q4 Revenue \$14.0M-\$14.5M vs \$11.0M-\$12.0M

Financial news for LGND dated on 2013-11-25: Standard & Poors Announces Ligand Pharma Will Replace SHFL Entertainment in S&P SmallCap 600

Financial news for LGND dated on 2013-11-14: Ligand Pharmaceuticals Incorporated Sees FY2016 EPS Over \$3.18; Sees Sales Over \$106.0M

Financial news for LGND dated on 2013-11-14: Ligand Pharmaceuticals Incorporated Sees FY2015 EPS Over \$2.13; Sees Sales Over \$81.0M

Financial news for LGND dated on 2013-11-14: Ligand Pharmaceuticals Incorporated Sees FY2014 EPS \$1.40-1.45; Sees Sales \$62.0M-64.0M

Financial news for LGND dated on 2013-11-12: Ligand Initiates Phase 1 Trial with Glucagon Receptor Antagonist for Type 2 Diabetes

Financial news for LGND dated on 2013-10-31: Brean Capital Downgrades Ligand Pharmaceuticals Incorporated to Hold, Removes \$45.00 PT

Financial news for LGND dated on 2013-10-30: Ligand Pharmaceuticals Incorporated Reports Q3 EPS of \$0.12 vs \$0.07 Est; Revenue of \$13.01M vs \$10.82M Est

Financial news for LGND dated on 2013-10-03: Ligand Highlights Pfizer's FDA Approval for DUAVEETM for Hot Flashes Related to Menopause

Financial news for LGND dated on 2013-09-24: Ligand Partner GSK Receives Marketing Authorization from EC for Additional Revolade Indication as Treatment for Chronic Hepatitis C-Associated Thrombocytopenia

Financial news for LGND dated on 2013-08-14: Ligand Enters Global License Agreement with CURx Pharmaceuticals for Captisol-Enabled Topiramate Injection

Financial news for LGND dated on 2013-08-02: Cantor Fitzgerald Downgrades Ligand Pharmaceuticals Incorporated to Sell, Raises PT to \$37.00

Financial news for LGND dated on 2013-08-01: Bloomberg Reporting Ligand Pharma, The Medicines Co. Have Mutually Terminated License Deal with CyDex Unit

Financial news for LGND dated on 2013-08-01: Ligand Pharmaceuticals Incorporated Reports Q2 EPS of \$0.07 vs \$0.06 Est; Revenue of \$9.58M vs \$9.30M Est

Financial news for LGND dated on 2013-07-26: Ligand Announces GlaxoSmithKline Wins Positive CHMP Opinion for REVLOADE

Financial news for LGND dated on 2013-07-26: Ligand Receives FDA Orphan Designation for Captisol-Enabled Topiramate Injection

Financial news for LGND dated on 2013-07-24: Ligand Pharma Announces License Deal with Ethicor for Oral Lasofoxifene

Financial news for LGND dated on 2013-07-22: Ligand Signs Global License Deal with Azure for Lasofoxifene

Financial news for LGND dated on 2013-07-01: Benzinga's Volume Movers

Financial news for LGND dated on 2013-06-24: Ligand Pharma Announces Preclinical Data for Glucagon Program

Financial news for LGND dated on 2013-06-20: Afternoon Market Movers

Financial news for LGND dated on 2013-06-20: Ligand Pharma Boosts Ownership Limit for BVF to 25% of Outstanding Shares

Financial news for LGND dated on 2013-05-29: Ligand Pharma Sees FY14 Adj. EPS Above \$1.05 vs \$0.95 Est.

Financial news for LGND dated on 2013-05-14: Ligand Partner Rib-X Initiates Phase 3 Trial of Captisol-enabled(tm) Delafloxacin IV

Financial news for LGND dated on 2013-05-08: Ligand Announces \$5M Buyback, Q1 Earnings

Financial news for LGND dated on 2013-05-08: Ligand Pharmaceuticals Incorporated Reports Q1 EPS of \$0.07 vs \$0.09 Est; Revenue of \$11.70M vs \$10.0M Est

Financial news for LGND dated on 2013-05-08: Ligand Pharmaceuticals Incorporated Reports Q1 EPS of \$0.06 vs \$0.09 Est; Revenue of \$11.65M vs \$10.0M Est

Financial news for LGND dated on 2013-04-22: Stocks Hitting 52-Week Highs

Financial news for LGND dated on 2013-03-18: UPDATE: Cantor Fitzgerald Raises PT on Ligand Pharmaceuticals on Announced Spectrum Partnership

Financial news for LGND dated on 2013-03-18: Cantor Fitzgerald Maintains Hold on Ligand Pharmaceuticals Incorporated, Raises PT to \$26.00

Financial news for LGND dated on 2013-03-14: Ligand Pharmaceuticals Incorporated Raises FY2013 EPS Guidance from \$0.35-0.39 to \$0.47-0.51 vs \$0.37 Est; Raises FY2013 Sales Guidance from \$41.0M-44.0M to \$43.0M-46.0M vs \$43.20M Est

Financial news for LGND dated on 2013-03-14: Ligand Pharmaceuticals Incorporated Sees Q1 EPS \$0.10-0.13 vs \$(0.01) Est; Sees Sales \$10.0M-11.0M vs \$8.04M Est

Financial news for LGND dated on 2013-03-14: Ligand, Spectrum Pharmaceuticals in Global License Agreement

Financial news for LGND dated on 2013-02-13: Ligand Pharmaceuticals Incorporated Sees FY2013 EPS \$0.35-0.39 vs \$0.39 Est; Sees Sales \$41.0M-44.0M vs \$43.20M Est

Financial news for LGND dated on 2013-02-13: Ligand Pharmaceuticals Incorporated Reports Q4 EPS of \$0.13 vs \$0.21 Est; Revenue of \$13.64M vs \$13.27M Est

Financial news for LGND dated on 2013-01-09: Ligand Pharma Wins Equity Milestone Payment from Retrophin

Financial news for LGND dated on 2013-01-04: UPDATE: Cantor Fitzgerald Downgrades Ligand Pharmaceuticals to Hold, Lowers PT

Financial news for LGND dated on 2013-01-04: Cantor Fitzgerald Downgrades Ligand Pharmaceuticals Incorporated to Hold, Lowers PT to \$23.00

Financial news for LGND dated on 2012-12-13: FDA Accepts NDA for Pfizer, Ligand's Bazedoxifene/Conjugated Estrogens

Financial news for LGND dated on 2012-12-10: Ligand Pharma Begins Pivotal Trial of Captisol-Enabled Propylene Glycol-Free Melphalan for Multiple Myeloma Patients

Financial news for LGND dated on 2012-12-07: UPDATE: Cantor Fitzgerald Reiterates Buy Rating, Raises PT on Ligand Pharmaceuticals

Financial news for LGND dated on 2012-12-07: Cantor Fitzgerald Maintains Buy on Ligand Pharmaceuticals Incorporated, Raises PT to \$28.00

Financial news for LGND dated on 2012-12-04: UPDATE: Ligand Pharmaceuticals Incorporated Sees FY2012 EPS \$(0.09)-(0.13)

Financial news for LGND dated on 2012-12-04: UPDATE: Ligand Pharmaceuticals Incorporated Sees Q4 EPS \$0.14-0.18 vs \$0.26 Est

Financial news for LGND dated on 2012-12-04: Ligand Pharmaceuticals Incorporated Sees FY2013 EPS Above \$0.35 vs \$0.43 Est; Sees Sales \$41.0M-44.0M vs \$45.0M Est

Financial news for LGND dated on 2012-12-04: UPDATE: Ligand Sees FY14 Sales More Than \$60M, EPS Above \$1.05

Financial news for LGND dated on 2012-11-19: Benzinga's Volume Movers

Financial news for LGND dated on 2012-11-19: Ligand Pharma Resumes Up 8.5%

Financial news for LGND dated on 2012-11-19: Ligand Pharma to Resume Trading at 9:45AM EST

Financial news for LGND dated on 2012-11-19: Ligand Pharma, Glaxo Confirm PROMACTA Receives FDA Ok for New Indication

Financial news for LGND dated on 2012-11-19: Hearing Ligand Pharma's Promacta Has Been Approved for the Treatment of HepC Patients with Low Blood Platelet Counts

Financial news for LGND dated on 2012-11-19: Ligand Pharma Halted with News Pending

Financial news for LGND dated on 2012-11-13: Ligand Pharma Announces Preclinical Data

for LG-7501

Financial news for LGND dated on 2012-11-05: Ligand Pharmaceuticals Reports Q3 EPS \$-0.01 vs \$-0.03 Est; Revenues \$6.4M vs \$6.08M Est

Financial news for LGND dated on 2012-10-22: UPDATE: Ligand Guides Q4 Revenue About \$13M, Had Seen \$11M vs \$10.8M Est; Guides Q3 Revenue \$6M, Had Seen \$8M vs \$8.4M Est

Financial news for LGND dated on 2012-10-22: Ligand to Receive \$2 Million Milestone Payment from Merck; Re-Affirms FY Forecast

Financial news for LGND dated on 2012-08-08: Ligand Pharmaceuticals Reports Q2 EPS \$-0.20 May Not Compare to \$-0.02 Est; Revenues \$5.7M vs \$7.13M Est

Financial news for LGND dated on 2012-07-25: Ligand Partner GlaxoSmithKline Announces Priority Review for Supplemental New Drug Application for Promacta(r) for the Treatment of Thrombocytopenia in Adult Patients with Chronic Hepatitis C Infection

Financial news for LGND dated on 2012-07-23: UPDATE: Cantor Fitzgerald Raises PT on Ligand Pharmaceuticals from \$19 to \$24

Financial news for LGND dated on 2012-07-20: Ligand Pharmaceuticals Spiking Higher in Onyx Kyprolis Approval

Financial news for LGND dated on 2012-07-19: Ligand Partner Pfizer Announces European Medicines Agency Accepts Regulatory Submission for Bazedoxifene

Financial news for LGND dated on 2012-06-20: Ligand Pharmaceuticals Spikes Higher After-Hours on Positive FDA Panel Vote on Onyx Pharmaceuticals' Kyprolis, Ligand to Receive Royalties

Financial news for LGND dated on 2012-06-20: Ligand Pharmaceuticals Spikes to Highs of Day; Company will Receive Royalty on Onyx Pharmaceuticals' Kyprolis Sales

Financial news for LGND dated on 2012-06-11: Ligand Announces Positive Preclinical Data on LGD-6972 at the American Diabetes Association's 72nd Scientific Sessions

Financial news for LGND dated on 2012-06-07: Cantor Fitzgerald Initiates Ligand Pharmaceuticals at Buy, \$19 PT

Financial news for LGND dated on 2012-03-26: Ligand Pharma Files \$30M Share Shelf

Financial news for LGND dated on 2012-02-21: Ligand Licenses DARA Program to Retrophin; Potential For Over \$75 Million In Milestone Payments to Ligand Plus Royalties

Financial news for LGND dated on 2012-02-08: MLV & Co Affirms Ligand Pharmaceuticals Buy, \$30 PT

Financial news for LGND dated on 2012-02-02: From Earlier: Ligand Presents Full Data from Successful Phase II Trial of Captisol-Enabled, Propylene Glycol-Free Melphalan

Financial news for LGND dated on 2011-12-21: Ligand Enters into Platform Captisol License and Supply Agreements with Lilly; Terms Not Disclosed

Financial news for LGND dated on 2011-12-12: Ligand Announces Positive Preclinical Data

Financial news for LGND dated on 2011-11-22: Griffin Securities Initiates Ligand Pharma at Buy, \$18 PT

Financial news for LGND dated on 2011-11-14: Edison Investment Research Expects Growth for Ligand Pharmaceuticals

Financial news for LGND dated on 2011-11-11: McNicoll, Lewis & Vlasko Maintains Buy Rating and \$30 PT on Ligand Pharmaceuticals

Financial news for LGND dated on 2011-11-07: Ligand Announces Positive Preclinical Data on IRAK4 Program at the 2011 American College of Rheumatology Annual Scientific Meeting

Financial news for LGND dated on 2011-11-07: McNicoll Lewis & Vlasko Maintains Buy Rating and \$30 PT on Ligand Pharmaceuticals

Financial news for LGND dated on 2011-11-02: Are Upcoming Study Results Spurring Insider Buying at Ligand Pharmaceuticals?

Financial news for LGND dated on 2011-11-02: Ligand Announces Successful Phase II Results for Captisol-Enabled Propylene Glycol-Free Melphalan

Financial news for LGND dated on 2011-10-19: Ligand Enters into Platform Captisol License Agreement with SAGE Therapeutics

Financial news for LGND dated on 2011-10-10: McNicoll, Lewis & Vlak Reiterates Ligand Pharmaceuticals Buy, \$30 Price Target

Financial news for LGND dated on 2011-10-10: Ligand to Get \$4M in Licensing Payments From China Pact

Financial news for LGND dated on 2011-10-10: Ligand Enters Into Global Licensing Agreement With Chiva Pharmaceuticals for Fablyn(r)

Financial news for LGND dated on 2011-09-08: Wednesday's Biotech Stocks Trading

Financial news for LGND dated on 2011-09-08: Mad Money Lightning Round: Cramer Likes Ligand Pharmaceuticals

Financial news for LGND dated on 2011-07-26: C.K. Cooper Reiterates Ligand Pharmaceuticals Buy, Raises PT

Financial news for LGND dated on 2011-06-20: Ligand Enters into Captisol Commercial Supply Agreement with Merck

Financial news for LGND dated on 2011-06-10: 8 Stocks With Significant Insider Buying

Financial news for LGND dated on 2011-06-06: Ligand Presents Phase IIa Data on Captisol-Enabled, Propylene Glycol-Free Melphalan at ASCO 2011

Financial news for LGND dated on 2011-06-06: Ligand Presents Multi-Dose Phase I Data on Lead SARM Molecule LGD-4033 at the Endocrine Society Annual Meeting

Financial news for LGND dated on 2011-06-03: Ligand and Medicines Company Agree to Worldwide License for Proprietary Captisol(r)-Enabled Intravenous Formulation of Clopidogrel

Financial news for LGND dated on 2011-04-20: Ligand Partner Prism Pharmaceuticals To Be Acquired By Baxter (LGND, BAX)

Financial news for LGND dated on 2011-04-18: Ligand Names Matthew W. Foehr COO

Financial news for LGND dated on 2011-02-28: Benzinga's Volume Movers (ARGN, OSTK, MALL, LGND)

Financial news for LGND dated on 2011-01-26: Ligand Acquires CyDex Pharmaceuticals for \$35.5M

Financial news for LGND dated on 2011-01-06: Ligand Forms Alliance with Chiva Pharmaceuticals

Financial news for LGND dated on 2010-12-22: Ligand Earns \$1 Million Upfront Payment from Pfizer

Financial news for LGND dated on 2010-11-19: Ligand 1 for 6 Reverse Stock Split Effective Today

Financial news for LGND dated on 2010-11-09: Ligand Announces 1-for-6 Reverse Stock Split

Financial news for LGND dated on 2010-11-02: Ligand Awarded \$2 Million from U.S. Government

Financial news for LGND dated on 2010-10-08: Ligand Appoints Sunil Patel to Board of Directors

Financial news for LGND dated on 2010-09-17: Ligand Enters into Agreement with Proximagen for CXCR4 Target

Financial news for LGND dated on 2010-03-21: How Will Obama-Care Play Into The Markets And ETFs?

Financial news for LGND dated on 2009-12-24: Ligand (LGND) Completes Neurogen (NRGN) Acquisition

Financial news for LGND dated on 2009-11-20: Benzinga's Top Pre- Market Gainers (TRBN, LGND, DYAX, VRGY, HIBB, NLST)

Financial news for LGND dated on 2009-10-27: Ligand (LGND) to Buy Metabasis (MBRX) for Cash of \$3.2M and Contingent Value Rights

